Skip to main content

procainamide

Generic: PROCAINAMIDE HYDROCHLORIDE·Brand: PROCAINAMIDE HYDROCHLORIDE, PROCAN, PROCAN SR, PROCANBID, PROCAPAN, PRONESTYL, PRONESTYL-SR

procainamide: sourced relationships with 1 company · 1 FDA decision.

procainamide evidence translation

What we can confirm

What it means

Source-backed records connect procainamide to NEXS; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could procainamide → NEXS affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Dated Pipeline Records (2)
CompanyDated record stage
NEXUS BIOPHARMA INC (NEXS)
Reported 2017-10-13 · Current development: unknownSource
Approved
NEXUS BIOPHARMA INC (NEXS)
Reported 2017-10-13 · Current development: unknownSource
Approved
FDA Decisions1 records
ApprovalINDICATIONS AND USAGE Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other ant(NEXS)FDA ↗
ANDA206332UNKNOWNStandardOtherInjectable

Frequently asked questions

Which companies have sourced relationships with procainamide?

procainamide has dated SEC/FDA relationship records for NEXUS BIOPHARMA INC.

What is procainamide's latest FDA decision?

The most recent tracked FDA decision for procainamide is Approval for INDICATIONS AND USAGE Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other ant, dated October 13, 2017.